1-4 of 4
Joseph Skitzki
Close
Sort by
Journal Articles

Targeting the X-Linked Inhibitor of Apoptosis Protein (XIAP) Can Promote Tumor Cell Death, and Increase the Cytotoxic Effects of Chemotherapy Agents in in Vitro and In Vivo Models of Rituximab-Resistant Lymphoma

Kyle L. Runckel, BS, Cory Mavis, MSc, Joseph Skitzki, Juan J Gu, PhD, Francisco J. Hernandez-Ilizaliturri, MD, Myron S. Czuczman, MD
Journal: Blood
Blood (2015) 126 (23): 590.
https://doi.org/10.1182/blood.V126.23.590.590
Published: 2015
Journal Articles

The SMAC Mimetic Lcl-161 Augments the in Vitro and in Vivo anti-Tumor Activity of Rituximab and Chemotherapy in Rituximab Relapse/Refractory Lymphoma Models

Kyle L. Runckel, BS, Joseph Skitzki, MD, Francisco Hernandez, MD, Myron S. Czuczman, MD
Journal: Blood
Blood (2014) 124 (21): 3110.
https://doi.org/10.1182/blood.V124.21.3110.3110
Published: 2014
Journal Articles

Ixazomib, An Investigational Orally Bioavailable Proteasome Inhibitor, Increases p21 Expression Inducing Caspase-Dependent Cell Death, Cell-Cycle Arrest, and In B-Cell Lymphoma Pre-Clinical Models

Cory Mavis, BSc, MSc, Juan Gu, PhD, Joseph Skitzki, MD, Francisco Hernandez, MD, Myron S. Czuczman, MD
Journal: Blood
Blood (2013) 122 (21): 1828.
https://doi.org/10.1182/blood.V122.21.1828.1828
Published: 2013
Journal Articles

The SMAC Mimetic Lcl-161 Demonstrates Anti-Tumor Activity As a Single Agent and Decreases the Apoptotic Threshold of Chemotherapy Agents in Rituximab-Chemotherapy Sensitive and Resistant Lymphoma Pre-Clinical Models

Kyle Runckel, BS, Cory Mavis, BSc, MSc, Joseph Skitzki, MD, Myron S. Czuczman, MD, Francisco J. Hernandez-Ilizaliturri, MD
Journal: Blood
Blood (2012) 120 (21): 61.
https://doi.org/10.1182/blood.V120.21.61.61
Published: 2012